For the quarter ended June 2026, McKesson (MCK Quick QuoteMCK - Free Report) reported revenue of $105.38 billion, up 7.7% over the same period last year. EPS came in at $9.93, compared to $8.26 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $104.39 billion, representing a surprise of +0.95%. The company delivered an EPS surprise of +5.19%, with the consensus EPS estimate being $9.44.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- North American Pharmaceutical: $86.77 billion versus the two-analyst average estimate of $86.53 billion. The reported number represents a year-over-year change of -3.5%.
• Revenue- Prescription Technology Solutions: $1.57 billion versus $1.5 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
• Revenue- Oncology & Multispecialty: $14.22 billion versus the two-analyst average estimate of $12.71 billion.
• Revenue- Medical-Surgical Solutions: $2.82 billion versus $2.79 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
• Adjusted Operating Profit- North American Pharmaceutical: $894 million compared to the $806.45 million average estimate based on two analysts.
• Adjusted Operating Profit- Medical-Surgical Solutions: $195 million versus $241.06 million estimated by two analysts on average.
• Adjusted Operating Profit- Corporate: $-144 million compared to the $-142.83 million average estimate based on two analysts.
• Adjusted Operating Profit- Oncology & Multispecialty: $405 million versus $367.82 million estimated by two analysts on average.
• Adjusted Operating Profit- Prescription Technology Solutions: $303 million compared to the $302.62 million average estimate based on two analysts.

View all Key Company Metrics for McKesson here>>>

Shares of McKesson have returned +2.9% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.